Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 30 entries
Sorted by: Best Match Show Resources per page
Metabolic abnormalities associated with HIV infection and antiretroviral therapy.

Current infectious disease reports

Fichtenbaum CJ.
PMID: 19094829
Curr Infect Dis Rep. 2009 Jan;11(1):84-92. doi: 10.1007/s11908-009-0012-8.

Although noted early in the HIV epidemic, metabolic abnormalities came to prominence when potent combination antiretroviral therapy was introduced. Complications associated with HIV infection and antiretroviral therapy include cardiovascular disease, lipid disorders, glucose metabolism disorders, adipose tissue disorders, bone...

Cite
Fichtenbaum CJ. Metabolic abnormalities associated with HIV infection and antiretroviral therapy. Curr Infect Dis Rep. 2009;11(1):84-92doi: 10.1007/s11908-009-0012-8.
Fichtenbaum, C. J. (2009). Metabolic abnormalities associated with HIV infection and antiretroviral therapy. Current infectious disease reports, 11(1), 84-92. https://doi.org/10.1007/s11908-009-0012-8
Fichtenbaum, Carl J. "Metabolic abnormalities associated with HIV infection and antiretroviral therapy." Current infectious disease reports vol. 11,1 (2009): 84-92. doi: https://doi.org/10.1007/s11908-009-0012-8
Fichtenbaum CJ. Metabolic abnormalities associated with HIV infection and antiretroviral therapy. Curr Infect Dis Rep. 2009 Jan;11(1):84-92. doi: 10.1007/s11908-009-0012-8. PMID: 19094829.
Copy Download .nbib Format: NLM
Distinctive clinical presentation and pathogenic specificities of anti-AK5 encephalitis.

Brain : a journal of neurology

Muñiz-Castrillo S, Hedou JJ, Ambati A, Jones D, Vogrig A, Pinto AL, Benaiteau M, de Broucker T, Fechtenbaum L, Labauge P, Murnane M, Nocon C, Taifas I, Vialatte de Pémille C, Psimaras D, Joubert B, Dubois V, Wucher V, Desestret V, Mignot E, Honnorat J.
PMID: 33843981
Brain. 2021 Oct 22;144(9):2709-2721. doi: 10.1093/brain/awab153.

Limbic encephalitis with antibodies against adenylate kinase 5 (AK5) has been difficult to characterize because of its rarity. In this study, we identified 10 new cases and reviewed 16 previously reported patients, investigating clinical features, IgG subclasses, human leucocyte...

Cite
Muñiz-Castrillo S, Hedou JJ, Ambati A, et al. Distinctive clinical presentation and pathogenic specificities of anti-AK5 encephalitis. Brain. 2021;144(9):2709-2721doi: 10.1093/brain/awab153.
Muñiz-Castrillo, S., Hedou, J. J., Ambati, A., Jones, D., Vogrig, A., Pinto, A. L., Benaiteau, M., de Broucker, T., Fechtenbaum, L., Labauge, P., Murnane, M., Nocon, C., Taifas, I., Vialatte de Pémille, C., Psimaras, D., Joubert, B., Dubois, V., Wucher, V., Desestret, V., Mignot, E., & Honnorat, J. (2021). Distinctive clinical presentation and pathogenic specificities of anti-AK5 encephalitis. Brain : a journal of neurology, 144(9), 2709-2721. https://doi.org/10.1093/brain/awab153
Muñiz-Castrillo, Sergio, et al. "Distinctive clinical presentation and pathogenic specificities of anti-AK5 encephalitis." Brain : a journal of neurology vol. 144,9 (2021): 2709-2721. doi: https://doi.org/10.1093/brain/awab153
Muñiz-Castrillo S, Hedou JJ, Ambati A, Jones D, Vogrig A, Pinto AL, Benaiteau M, de Broucker T, Fechtenbaum L, Labauge P, Murnane M, Nocon C, Taifas I, Vialatte de Pémille C, Psimaras D, Joubert B, Dubois V, Wucher V, Desestret V, Mignot E, Honnorat J. Distinctive clinical presentation and pathogenic specificities of anti-AK5 encephalitis. Brain. 2021 Oct 22;144(9):2709-2721. doi: 10.1093/brain/awab153. PMID: 33843981; PMCID: PMC8557339.
Copy Download .nbib Format: NLM
Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus.

Open forum infectious diseases

Kileel EM, Lo J, Malvestutto C, Fitch KV, Zanni MV, Fichtenbaum CJ, Overton ET, Okeke NL, Kumar P, Joao E, Aberg JA, Martinez E, Currier JS, Douglas PS, Ribaudo HJ, Grinspoon SK.
PMID: 34888395
Open Forum Infect Dis. 2021 Nov 20;8(12):ofab537. doi: 10.1093/ofid/ofab537. eCollection 2021 Dec.

BACKGROUND: Emerging data demonstrate that the use of integrase inhibitor (INSTI)-based antiretroviral treatment (ART) is associated with increased weight, but the cardiometabolic health consequences of increased weight remains poorly understood.METHODS: This analysis examined INSTI use (>6 months) at entry...

Cite
Kileel EM, Lo J, Malvestutto C, et al. Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus. Open Forum Infect Dis. 2021;8(12):ofab537doi: 10.1093/ofid/ofab537.
Kileel, E. M., Lo, J., Malvestutto, C., Fitch, K. V., Zanni, M. V., Fichtenbaum, C. J., Overton, E. T., Okeke, N. L., Kumar, P., Joao, E., Aberg, J. A., Martinez, E., Currier, J. S., Douglas, P. S., Ribaudo, H. J., & Grinspoon, S. K. (2021). Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus. Open forum infectious diseases, 8(12), ofab537. https://doi.org/10.1093/ofid/ofab537
Kileel, Emma M, et al. "Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus." Open forum infectious diseases vol. 8,12 (2021): ofab537. doi: https://doi.org/10.1093/ofid/ofab537
Kileel EM, Lo J, Malvestutto C, Fitch KV, Zanni MV, Fichtenbaum CJ, Overton ET, Okeke NL, Kumar P, Joao E, Aberg JA, Martinez E, Currier JS, Douglas PS, Ribaudo HJ, Grinspoon SK. Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus. Open Forum Infect Dis. 2021 Nov 20;8(12):ofab537. doi: 10.1093/ofid/ofab537. eCollection 2021 Dec. PMID: 34888395; PMCID: PMC8651160.
Copy Download .nbib Format: NLM
Fully automated opportunistic screening of vertebral fractures and osteoporosis on more than 150,000 routine computed tomography scans.

Rheumatology (Oxford, England)

Roux C, Rozes A, Reizine D, Hajage D, Daniel C, Maire A, Bréant S, Taright N, Gordon R, Fechtenbaum J, Kolta S, Feydy A, Briot K, Tubach F.
PMID: 34850864
Rheumatology (Oxford). 2021 Nov 30; doi: 10.1093/rheumatology/keab878. Epub 2021 Nov 30.

OBJECTIVE: Osteoporosis is underdiagnosed and undertreated, although severe complications of osteoporotic fractures, including vertebral fractures, are well known. This study sought to assess the feasibility and results of an opportunistic screening of vertebral fractures and osteoporosis in a large...

Cite
Roux C, Rozes A, Reizine D, et al. Fully automated opportunistic screening of vertebral fractures and osteoporosis on more than 150,000 routine computed tomography scans. Rheumatology (Oxford). 2021;doi: 10.1093/rheumatology/keab878.
Roux, C., Rozes, A., Reizine, D., Hajage, D., Daniel, C., Maire, A., Bréant, S., Taright, N., Gordon, R., Fechtenbaum, J., Kolta, S., Feydy, A., Briot, K., & Tubach, F. (2021). Fully automated opportunistic screening of vertebral fractures and osteoporosis on more than 150,000 routine computed tomography scans. Rheumatology (Oxford, England), . https://doi.org/10.1093/rheumatology/keab878
Roux, Christian, et al. "Fully automated opportunistic screening of vertebral fractures and osteoporosis on more than 150,000 routine computed tomography scans." Rheumatology (Oxford, England) vol. (2021). doi: https://doi.org/10.1093/rheumatology/keab878
Roux C, Rozes A, Reizine D, Hajage D, Daniel C, Maire A, Bréant S, Taright N, Gordon R, Fechtenbaum J, Kolta S, Feydy A, Briot K, Tubach F. Fully automated opportunistic screening of vertebral fractures and osteoporosis on more than 150,000 routine computed tomography scans. Rheumatology (Oxford). 2021 Nov 30; doi: 10.1093/rheumatology/keab878. Epub 2021 Nov 30. PMID: 34850864.
Copy Download .nbib Format: NLM
Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention.

JAMA network open

Hoffmann U, Lu MT, Foldyna B, Zanni MV, Karady J, Taron J, Zhai BK, Burdo T, Fitch KV, Kileel EM, Williams K, Fichtenbaum CJ, Overton ET, Malvestutto C, Aberg J, Currier J, Sponseller CA, Melbourne K, Floris-Moore M, Van Dam C, Keefer MC, Koletar SL, Douglas PS, Ribaudo H, Mayrhofer T, Grinspoon SK.
PMID: 34185068
JAMA Netw Open. 2021 Jun 01;4(6):e2114923. doi: 10.1001/jamanetworkopen.2021.14923.

IMPORTANCE: Cardiovascular disease (CVD) is increased among people with HIV (PWH), but little is known regarding the prevalence and extent of coronary artery disease (CAD) and associated biological factors in PWH with low to moderate traditional CVD risk.OBJECTIVES: To...

Cite
Hoffmann U, Lu MT, Foldyna B, et al. Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention. JAMA Netw Open. 2021;4(6):e2114923doi: 10.1001/jamanetworkopen.2021.14923.
Hoffmann, U., Lu, M. T., Foldyna, B., Zanni, M. V., Karady, J., Taron, J., Zhai, B. K., Burdo, T., Fitch, K. V., Kileel, E. M., Williams, K., Fichtenbaum, C. J., Overton, E. T., Malvestutto, C., Aberg, J., Currier, J., Sponseller, C. A., Melbourne, K., Floris-Moore, M., Van Dam, C., Keefer, M. C., Koletar, S. L., Douglas, P. S., Ribaudo, H., Mayrhofer, T., Grinspoon, S. K. (2021). Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention. JAMA network open, 4(6), e2114923. https://doi.org/10.1001/jamanetworkopen.2021.14923
Hoffmann, Udo, et al. "Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention." JAMA network open vol. 4,6 (2021): e2114923. doi: https://doi.org/10.1001/jamanetworkopen.2021.14923
Hoffmann U, Lu MT, Foldyna B, Zanni MV, Karady J, Taron J, Zhai BK, Burdo T, Fitch KV, Kileel EM, Williams K, Fichtenbaum CJ, Overton ET, Malvestutto C, Aberg J, Currier J, Sponseller CA, Melbourne K, Floris-Moore M, Van Dam C, Keefer MC, Koletar SL, Douglas PS, Ribaudo H, Mayrhofer T, Grinspoon SK. Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention. JAMA Netw Open. 2021 Jun 01;4(6):e2114923. doi: 10.1001/jamanetworkopen.2021.14923. PMID: 34185068; PMCID: PMC8243232.
Copy Download .nbib Format: NLM
Adherence to and patient's knowledge of self-management of subcutaneous biologic therapy in chronic inflammatory rheumatic diseases: results of a multicentre cross-sectional study.

Clinical and experimental rheumatology

Gaud-Listrat V, Lopez-Medina C, Hudry C, Nguyen M, Lebrun-Foisnet A, Sacchi A, Labatide Alanore S, Dernis E, Le Devic P, Fechtenbaum J, Richard-Miceli C, Le Goux P, Dadoun S, Moltό A, Blanchais-Behr A, Neveu S, Benhamou M, Giraud B, Roux C, Dougados M.
PMID: 34128794
Clin Exp Rheumatol. 2021 May 28; Epub 2021 May 28.

OBJECTIVES: Non-adherence to biologic therapy is an issue in chronic inflammatory rheumatic diseases (CIRDs) and might be related to poor patient knowledge of the risk of these therapies. Our aim here was to evaluate the level of patient adherence...

Cite
Gaud-Listrat V, Lopez-Medina C, Hudry C, et al. Adherence to and patient's knowledge of self-management of subcutaneous biologic therapy in chronic inflammatory rheumatic diseases: results of a multicentre cross-sectional study. Clin Exp Rheumatol. 2021;
Gaud-Listrat, V., Lopez-Medina, C., Hudry, C., Nguyen, M., Lebrun-Foisnet, A., Sacchi, A., Labatide Alanore, S., Dernis, E., Le Devic, P., Fechtenbaum, J., Richard-Miceli, C., Le Goux, P., Dadoun, S., Moltό, A., Blanchais-Behr, A., Neveu, S., Benhamou, M., Giraud, B., Roux, C., Dougados, M. (2021). Adherence to and patient's knowledge of self-management of subcutaneous biologic therapy in chronic inflammatory rheumatic diseases: results of a multicentre cross-sectional study. Clinical and experimental rheumatology, .
Gaud-Listrat, Veronique, et al. "Adherence to and patient's knowledge of self-management of subcutaneous biologic therapy in chronic inflammatory rheumatic diseases: results of a multicentre cross-sectional study." Clinical and experimental rheumatology vol. (2021).
Gaud-Listrat V, Lopez-Medina C, Hudry C, Nguyen M, Lebrun-Foisnet A, Sacchi A, Labatide Alanore S, Dernis E, Le Devic P, Fechtenbaum J, Richard-Miceli C, Le Goux P, Dadoun S, Moltό A, Blanchais-Behr A, Neveu S, Benhamou M, Giraud B, Roux C, Dougados M. Adherence to and patient's knowledge of self-management of subcutaneous biologic therapy in chronic inflammatory rheumatic diseases: results of a multicentre cross-sectional study. Clin Exp Rheumatol. 2021 May 28; Epub 2021 May 28. PMID: 34128794.
Copy Download .nbib Format: NLM
Capsular bag performance of a novel hydrophobic acrylic single-piece intraocular lens: Two-year results of a randomised controlled trial.

European journal of ophthalmology

Fișuș AD, Hirnschall ND, Maedel S, Fichtenbaum M, Draschl P, Findl O.
PMID: 32993380
Eur J Ophthalmol. 2021 Sep;31(5):2377-2382. doi: 10.1177/1120672120960591. Epub 2020 Sep 29.

PURPOSE: To determine the visual outcome, intraocular lens (IOL) stability and posterior capsule opacification (PCO) rate of a hydrophobic acrylic intraocular lens.SETTING: Vienna Institute for Research in Ocular Surgery, Hanusch Hospital, Vienna, Austria.DESIGN: This double-masked randomised study included patients...

Cite
Fișuș AD, Hirnschall ND, Maedel S, et al. Capsular bag performance of a novel hydrophobic acrylic single-piece intraocular lens: Two-year results of a randomised controlled trial. Eur J Ophthalmol. 2020;31(5):2377-2382doi: 10.1177/1120672120960591.
Fișuș, A. D., Hirnschall, N. D., Maedel, S., Fichtenbaum, M., Draschl, P., & Findl, O. (2021). Capsular bag performance of a novel hydrophobic acrylic single-piece intraocular lens: Two-year results of a randomised controlled trial. European journal of ophthalmology, 31(5), 2377-2382. https://doi.org/10.1177/1120672120960591
Fișuș, Andreea D, et al. "Capsular bag performance of a novel hydrophobic acrylic single-piece intraocular lens: Two-year results of a randomised controlled trial." European journal of ophthalmology vol. 31,5 (2021): 2377-2382. doi: https://doi.org/10.1177/1120672120960591
Fișuș AD, Hirnschall ND, Maedel S, Fichtenbaum M, Draschl P, Findl O. Capsular bag performance of a novel hydrophobic acrylic single-piece intraocular lens: Two-year results of a randomised controlled trial. Eur J Ophthalmol. 2021 Sep;31(5):2377-2382. doi: 10.1177/1120672120960591. Epub 2020 Sep 29. PMID: 32993380.
Copy Download .nbib Format: NLM
No Significant Changes to Residual Viremia After Switch to Dolutegravir and Lamivudine in a Randomized Trial.

Open forum infectious diseases

Li JZ, Sax PE, Marconi VC, Fajnzylber J, Berzins B, Nyaku AN, Fichtenbaum CJ, Wilkin T, Benson CA, Koletar SL, Lorenzo-Redondo R, Taiwo BO.
PMID: 30895201
Open Forum Infect Dis. 2019 Feb 11;6(3):ofz056. doi: 10.1093/ofid/ofz056. eCollection 2019 Mar.

In the ASPIRE trial, antiretroviral therapy (ART) switch to dolutegravir plus lamivudine (DTG+3TC) was comparable to 3-drug ART in maintaining viral suppression by standard viral load assays. We used an ultrasensitive assay to assess whether this switch led to...

Cite
Li JZ, Sax PE, Marconi VC, et al. No Significant Changes to Residual Viremia After Switch to Dolutegravir and Lamivudine in a Randomized Trial. Open Forum Infect Dis. 2019;6(3):ofz056doi: 10.1093/ofid/ofz056.
Li, J. Z., Sax, P. E., Marconi, V. C., Fajnzylber, J., Berzins, B., Nyaku, A. N., Fichtenbaum, C. J., Wilkin, T., Benson, C. A., Koletar, S. L., Lorenzo-Redondo, R., & Taiwo, B. O. (2019). No Significant Changes to Residual Viremia After Switch to Dolutegravir and Lamivudine in a Randomized Trial. Open forum infectious diseases, 6(3), ofz056. https://doi.org/10.1093/ofid/ofz056
Li, Jonathan Z, et al. "No Significant Changes to Residual Viremia After Switch to Dolutegravir and Lamivudine in a Randomized Trial." Open forum infectious diseases vol. 6,3 (2019): ofz056. doi: https://doi.org/10.1093/ofid/ofz056
Li JZ, Sax PE, Marconi VC, Fajnzylber J, Berzins B, Nyaku AN, Fichtenbaum CJ, Wilkin T, Benson CA, Koletar SL, Lorenzo-Redondo R, Taiwo BO. No Significant Changes to Residual Viremia After Switch to Dolutegravir and Lamivudine in a Randomized Trial. Open Forum Infect Dis. 2019 Feb 11;6(3):ofz056. doi: 10.1093/ofid/ofz056. eCollection 2019 Mar. PMID: 30895201; PMCID: PMC6419983.
Copy Download .nbib Format: NLM
Is it time to retire efavirenz as a first-line option worldwide?.

AIDS (London, England)

Guanira JV, Fichtenbaum CJ.
PMID: 34934022
AIDS. 2022 Feb 01;36(2):317-318. doi: 10.1097/QAD.0000000000003101.

No abstract available.

Cite
Guanira JV, Fichtenbaum CJ. Is it time to retire efavirenz as a first-line option worldwide?. AIDS. 2022;36(2):317-318doi: 10.1097/QAD.0000000000003101.
Guanira, J. V., & Fichtenbaum, C. J. (2022). Is it time to retire efavirenz as a first-line option worldwide?. AIDS (London, England), 36(2), 317-318. https://doi.org/10.1097/QAD.0000000000003101
Guanira, Juan V, and Fichtenbaum, Carl J. "Is it time to retire efavirenz as a first-line option worldwide?." AIDS (London, England) vol. 36,2 (2022): 317-318. doi: https://doi.org/10.1097/QAD.0000000000003101
Guanira JV, Fichtenbaum CJ. Is it time to retire efavirenz as a first-line option worldwide?. AIDS. 2022 Feb 01;36(2):317-318. doi: 10.1097/QAD.0000000000003101. PMID: 34934022.
Copy Download .nbib Format: NLM
Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Douglas PS, Umbleja T, Bloomfield GS, Fichtenbaum CJ, Zanni MV, Overton ET, Fitch KV, Kileel EM, Aberg JA, Currier J, Sponseller CA, Melbourne K, Avihingsanon A, Bustorff F, Estrada V, Ruxrungtham K, Saumoy M, Navar AM, Hoffmann U, Ribaudo HJ, Grinspoon S.
PMID: 34134131
Clin Infect Dis. 2021 Dec 06;73(11):2009-2022. doi: 10.1093/cid/ciab552.

BACKGROUND: In addition to traditional cardiovascular (CV) risk factors, antiretroviral therapy, lifestyle, and human immunodeficiency virus (HIV)-related factors may contribute to future CV events in persons with HIV (PWH).METHODS: Among participants in the global REPRIEVE randomized trial, we characterized...

Cite
Douglas PS, Umbleja T, Bloomfield GS, et al. Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial. Clin Infect Dis. 2021;73(11):2009-2022doi: 10.1093/cid/ciab552.
Douglas, P. S., Umbleja, T., Bloomfield, G. S., Fichtenbaum, C. J., Zanni, M. V., Overton, E. T., Fitch, K. V., Kileel, E. M., Aberg, J. A., Currier, J., Sponseller, C. A., Melbourne, K., Avihingsanon, A., Bustorff, F., Estrada, V., Ruxrungtham, K., Saumoy, M., Navar, A. M., Hoffmann, U., Ribaudo, H. J., & Grinspoon, S. (2021). Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 73(11), 2009-2022. https://doi.org/10.1093/cid/ciab552
Douglas, Pamela S, et al. "Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America vol. 73,11 (2021): 2009-2022. doi: https://doi.org/10.1093/cid/ciab552
Douglas PS, Umbleja T, Bloomfield GS, Fichtenbaum CJ, Zanni MV, Overton ET, Fitch KV, Kileel EM, Aberg JA, Currier J, Sponseller CA, Melbourne K, Avihingsanon A, Bustorff F, Estrada V, Ruxrungtham K, Saumoy M, Navar AM, Hoffmann U, Ribaudo HJ, Grinspoon S. Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial. Clin Infect Dis. 2021 Dec 06;73(11):2009-2022. doi: 10.1093/cid/ciab552. PMID: 34134131.
Copy Download .nbib Format: NLM
COVID-19 Vaccination Rates in a Global HIV Cohort.

The Journal of infectious diseases

Fulda ES, Fitch KV, Overton ET, Zanni MV, Aberg JA, Currier JS, Lu MT, Malvestutto C, Fichtenbaum CJ, Martinez E, Umbleja T, Douglas PS, Ribaudo HJ, Grinspoon SK.
PMID: 34794178
J Infect Dis. 2021 Nov 18; doi: 10.1093/infdis/jiab575. Epub 2021 Nov 18.

Little is known regarding COVID-19 vaccination rates in people with HIV (PWH), a vulnerable population with significant morbidity from COVID-19. We assessed COVID-19 vaccination rates among 6952 PWH in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)...

Cite
Fulda ES, Fitch KV, Overton ET, et al. COVID-19 Vaccination Rates in a Global HIV Cohort. J Infect Dis. 2021;doi: 10.1093/infdis/jiab575.
Fulda, E. S., Fitch, K. V., Overton, E. T., Zanni, M. V., Aberg, J. A., Currier, J. S., Lu, M. T., Malvestutto, C., Fichtenbaum, C. J., Martinez, E., Umbleja, T., Douglas, P. S., Ribaudo, H. J., & Grinspoon, S. K. (2021). COVID-19 Vaccination Rates in a Global HIV Cohort. The Journal of infectious diseases, . https://doi.org/10.1093/infdis/jiab575
Fulda, Evelynne S, et al. "COVID-19 Vaccination Rates in a Global HIV Cohort." The Journal of infectious diseases vol. (2021). doi: https://doi.org/10.1093/infdis/jiab575
Fulda ES, Fitch KV, Overton ET, Zanni MV, Aberg JA, Currier JS, Lu MT, Malvestutto C, Fichtenbaum CJ, Martinez E, Umbleja T, Douglas PS, Ribaudo HJ, Grinspoon SK. COVID-19 Vaccination Rates in a Global HIV Cohort. J Infect Dis. 2021 Nov 18; doi: 10.1093/infdis/jiab575. Epub 2021 Nov 18. PMID: 34794178.
Copy Download .nbib Format: NLM
Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Douglas PS, Umbleja T, Bloomfield GS, Fichtenbaum CJ, Zanni MV, Overton ET, Fitch KV, Kileel EM, Aberg JA, Currier J, Sponseller CA, Melbourne K, Avihingsanon A, Bustorff F, Estrada V, Ruxrungtham K, Saumoy M, Navar AM, Hoffmann U, Ribaudo HJ, Grinspoon S.
PMID: 34134131
Clin Infect Dis. 2021 Dec 06;73(11):2009-2022. doi: 10.1093/cid/ciab552.

BACKGROUND: In addition to traditional cardiovascular (CV) risk factors, antiretroviral therapy, lifestyle, and human immunodeficiency virus (HIV)-related factors may contribute to future CV events in persons with HIV (PWH).METHODS: Among participants in the global REPRIEVE randomized trial, we characterized...

Cite
Douglas PS, Umbleja T, Bloomfield GS, et al. Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial. Clin Infect Dis. 2021;73(11):2009-2022doi: 10.1093/cid/ciab552.
Douglas, P. S., Umbleja, T., Bloomfield, G. S., Fichtenbaum, C. J., Zanni, M. V., Overton, E. T., Fitch, K. V., Kileel, E. M., Aberg, J. A., Currier, J., Sponseller, C. A., Melbourne, K., Avihingsanon, A., Bustorff, F., Estrada, V., Ruxrungtham, K., Saumoy, M., Navar, A. M., Hoffmann, U., Ribaudo, H. J., & Grinspoon, S. (2021). Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 73(11), 2009-2022. https://doi.org/10.1093/cid/ciab552
Douglas, Pamela S, et al. "Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America vol. 73,11 (2021): 2009-2022. doi: https://doi.org/10.1093/cid/ciab552
Douglas PS, Umbleja T, Bloomfield GS, Fichtenbaum CJ, Zanni MV, Overton ET, Fitch KV, Kileel EM, Aberg JA, Currier J, Sponseller CA, Melbourne K, Avihingsanon A, Bustorff F, Estrada V, Ruxrungtham K, Saumoy M, Navar AM, Hoffmann U, Ribaudo HJ, Grinspoon S. Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial. Clin Infect Dis. 2021 Dec 06;73(11):2009-2022. doi: 10.1093/cid/ciab552. PMID: 34134131; PMCID: PMC8664454.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 30 entries